A- A A+

Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease

(US Food and Drug Administration, 28.08.2019)

https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/hepatitis-c-medicines-mavyret-zepatier-and-vosevi-drug-safety-communication-due-rare-occurrence